These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6348018)

  • 41. Prediction of drug dosage in patients with renal failure using data derived from normal subjects.
    Welling PG; Craig WA; Kunin CM
    Clin Pharmacol Ther; 1975 Jul; 18(1):45-52. PubMed ID: 1149361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Study of the serum half-life of a new cephalosporin in uraemic patients.
    Fillastre JP; Humbert G; Acar J; Malandain H; Robert M; Dubois D; Daufresne MF
    Proc Eur Dial Transplant Assoc; 1972; 9():577-80. PubMed ID: 4668933
    [No Abstract]   [Full Text] [Related]  

  • 44. Penetration of ceftazidime into serum, myometrium, endometrium, salpinges and subcutaneous tissue.
    Daschner FD; Petersen EE; Just HM; Hillemanns HG
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():247-9. PubMed ID: 6352627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fundamental and clinical studies on ceftazidime].
    Seiga K; Yamaji K; Sugiyama Y
    Jpn J Antibiot; 1984 Jan; 37(1):38-48. PubMed ID: 6374198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of the beta-lactamase stability of ceftazidime and eight other new cephalosporin antibiotics.
    Simpson IN; Plested SJ; Harper PB
    J Antimicrob Chemother; 1982 May; 9(5):357-68. PubMed ID: 7047482
    [No Abstract]   [Full Text] [Related]  

  • 47. Digoxin disposition kinetics in dogs before and during azotemia.
    Gierke KD; Perrier D; Mayersohn M; Marcus FI
    J Pharmacol Exp Ther; 1978 May; 205(2):459-64. PubMed ID: 641840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady-state moxalactam kinetics: comparisons with other cephalosporins.
    Garzone P; Lyon J; Yu VL; Zuravleff J; Diven W; Pasculle W
    Clin Pharmacol Ther; 1981 Jul; 30(1):86-94. PubMed ID: 6453677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of norfloxacin in renal failure.
    Fillastre JP; Hannedouche T; Leroy A; Humbert G
    J Antimicrob Chemother; 1984 Oct; 14(4):439. PubMed ID: 6238930
    [No Abstract]   [Full Text] [Related]  

  • 50. Serum half-lives and elimination rates of a new semi-synthetic cephalosporin, cephacetrile, in nephrectomized patients and in patients with impaired or normal renal function.
    Reutter F; Maurice NP
    Arzneimittelforschung; 1974 Sep; 24(9b):1466-8. PubMed ID: 4479804
    [No Abstract]   [Full Text] [Related]  

  • 51. Creatine and creatinine metabolism in uraemia.
    Bennett SE; Bevington A; Walls J
    Miner Electrolyte Metab; 1992; 18(2-5):192-5. PubMed ID: 1465056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics of moxalactam in renal failure.
    Wright N; Wills PJ; Wise R
    J Antimicrob Chemother; 1981 Nov; 8(5):395-9. PubMed ID: 6459316
    [No Abstract]   [Full Text] [Related]  

  • 53. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop.
    Poirel L; Naas T; Le Thomas I; Karim A; Bingen E; Nordmann P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3355-61. PubMed ID: 11709308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Pseudomonas aeruginosa meningitis with ceftazidime.
    Modai J; Meulemans A; Vittecoq D
    J Antimicrob Chemother; 1983 Feb; 11(2):198-9. PubMed ID: 6339463
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical pharmacokinetics of the third generation cephalosporins.
    Balant L; Dayer P; Auckenthaler R
    Clin Pharmacokinet; 1985; 10(2):101-43. PubMed ID: 3888488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of ceftazidime in renal failure.
    Fillastre JP; Humbert G; Olier B; Leguy F; Borsa F; Spenser GR
    J Antimicrob Chemother; 1983 May; 11(5):487-8. PubMed ID: 6348018
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of cephalexin in renal insufficiency.
    Regamey C; Humair L
    Postgrad Med J; 1971 Feb; 47():Suppl:69-78. PubMed ID: 5556195
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of decreased renal function on the pharmacokinetics of ceftazidime.
    Ackerman BH; Ross J; Tofte RW; Rotschafer JC
    Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefamandole kinetics in uremic patients undergoing hemodialysis.
    Gambertoglio JG; Aziz NS; Lin ET; Grausz H; Naughton JL; Benet LZ
    Clin Pharmacol Ther; 1979 Nov; 26(5):592-9. PubMed ID: 498702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.